ZFSW
ZFSW
Cancer vaccine developer
ZFSW, founded in July, 1995 and headquartered in Chongqing, is an anti-cancer vaccine developer. The founder is Jiang Rensheng. Listed on the SZSE on September 28, 2010, the company's major shareholders are Jiang Rensheng, Jiang Lingfeng and Wu Guanjiang. Rivals that have direct and indirect competition with ZFSW include Kintor, HitGen, Aprea Therapeutics, BridgeBio Pharma, etc.
- All
- News
- Analysis
- Research
Briefing Yesterday 10:21 AM
· Healthcare
Microchip diabetes mellitus new drug glipizide sodium approved in China
Briefing Updated 3 hours ago
· Healthcare
Kangyuan obtained tens of millions of yuan of round a financing for a long time and accelerated the application of jy108 dual anti drug ind
In depth
Healthcare
Bid for Molecular Tech in China's Early-Stage Cancer Detection Market
China, with a population of 1.4 billion, has one of the largest gene pools in the world. How does its DNA tech-based cancer detection industry look? Listed on Nasdaq in 2020, Genetron Holdings Limited (Genetron Health) is taking a leading role.
Sep 09, 2020 03:08 PM
Briefing Oct 08, 2021 10:27 AM
· Healthcare
Yiyi biological submitted ryzneuta to the European drug administration ™ Listing application accepted
Briefing Sep 30, 2021 02:41 PM
· Healthcare
AstraZeneca acquires Caelum Biosciences overweight rare diseases business
Research
Consumer Staples, Technology, HealthcareWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Research
Consumer Discretionary, Consumer Staples, IndustrialsTech for Global, Globalization Footprints of the Established and the New
May 29, 2020 08:30 PM
Research
Consumer Discretionary, Consumer Staples, IndustrialsLow-Carbon Industry Expansion - Key Studies From Chinese Companies
May 28, 2020 12:40 PM
Briefing Sep 27, 2021 11:57 AM
· Healthcare
Triarm therapeutics completed a round of financing of US $60 million
Briefing Sep 18, 2021 09:08 AM
· Healthcare
Puri benchmark obtained 150 million yuan of round B financing to promote the research and development of new drugs driven by multi omics data mining
Briefing Sep 13, 2021 02:15 PM
· Healthcare
Baiji Shenzhou welcomes the milestone of "going to sea" again, and PD-1 monoclonal antibody baizean ® The new drug marketing application for esophageal squamous cell carcinoma was accepted by FDA
Briefing Sep 03, 2021 05:42 PM
· Healthcare
Nuocheng Jianhua and kangnoah deepen strategic cooperation and develop first in class macromolecular innovative drugs
Insight
Healthcare
Sinopharm COVID Vaccine Receives WHO Emergency Use Certification
The Sinopharm Group’s COVID Vaccine is the sixth vaccine to receive safety, efficacy and quality verification from the World Health Organization (WHO). It is the first vaccine from a non-Western country to receive WHO certification.
May 11, 2021 03:35 AM
Briefing Sep 03, 2021 09:45 AM
· Healthcare
Yao Ming Ju Nuo Rui Qi orenzai was approved as the second car-t product in China
Briefing Aug 03, 2021 11:10 AM
· Healthcare
Monitoring of main funds of star mine: Top 10 list of early trading
Healthcare
Yunnan Baiyao's Revenue Rises 33%; Net Profit Falls 40% in 1Q 2021
On April 27, Yunnan Baiyao released a report for the first quarter of 2021 showing that the company's total operating revenue for the first quarter was 10.33 billion yuan, up 33.4% year-on-year; its operating profit was 880 million yuan, down 41.8% year-on-year; its net profit attributable to shareholders of the listed company was 760 million yuan.
Apr 30, 2021 02:07 AM
Briefing Jul 23, 2021 10:13 AM
· Healthcare
Pharmaceutical and biological stocks fell sharply in early trading
Briefing Jul 20, 2021 10:05 PM
US Senate committee to investigate the role of cryptocurrency in cyber crime
Briefing Jul 13, 2021 08:47 PM
· Healthcare
A breakthrough in cell therapy of solid tumor by Zhifei biological joint stock company
Briefing Jul 07, 2021 03:24 PM
· Healthcare
The first bank of China fund to release its second Quarterly Report
See more
Related Companies
EqualOcean Analysis
- Black Swans and Breakthroughs: China's Top 50 Innovative Public Firms in 2020
- China Speed: Two COVID-19 Vaccines Recognized by WHO
- After China's BNR and GTH Hit Nasdaq, Pan-Cancer Detector GRAIL Eyes IPO
- More Room for the Medical Device Market to Grow in China
- Tong Ren Tang: Any Hope for this Purveyor of Centuries-Old Chinese Medicines?
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.